Cite

HARVARD Citation

    Parker Kerrigan, B. et al. (2020). RNAi technology targeting the FGFR3-TACC3 fusion breakpoint: an opportunity for precision medicine. Neuro-oncology advances. 2 (1), p. . [Online]. 
  
Back to record